Beyond valganciclovir: A meta-analysis of letermovir’s safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantation

Abstract Background Cytomegalovirus (CMV) remains a major infectious cause of morbidity and graft dysfunction after solid organ transplantation (SOT). Valganciclovir (VGC) is effective for CMV prophylaxis but limited by myelotoxicity. Letermovir (LTV), a CMV terminase complex inhibitor, offers a non...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Muhammad Usman, Zhihan Yuan, Hao Yu, Xutao Chen, Zhuang Tang, Cheng Liu, Zhouhang Li, Wang He, Kewei Xu
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-03-01
Serija:	BMC Infectious Diseases
Teme:	Letermovir Valganciclovir Cytomegalovirus Solid organ transplantation Prophylaxis
Online dostop:	https://doi.org/10.1186/s12879-026-13022-1
Oznake:	Označite Brez oznak, prvi označite!